12 Sep 2008 11:40
Fulcrum Pharma Plc ("Fulcrum" or the "Company")
Director shareholding
Fulcrum (AIM: FUL), the drug development and regulatory services company, announces that it was notified on 11 September 2008 that, on 10 September, certain directors, including Frank Armstrong, the Company's new Chief Executive, and Grahame Cook, the recently appointed Chairman-designate, purchased ordinary shares in the Company at a price of 3.6p each as follows:
| Director | Number of shares acquired | Number of shares held in Company after acquisition | % of voting rights held following allocation |
| Dr Frank Armstrong | 600,000 | 600,000 | 0.05% |
| Grahame Cook | 600,000 | 600,000 | 0.05% |
| Geoffrey Smith | 500,000 | 4,482,744 | 0.38% |
Professor Sir Charles George, Chairman, said "I am delighted to see that our key directors, including our new chief executive and chairman-designate, have expressed their confidence in the Company's business and prospects by investing in the Company. I look forward to reporting on our progress in November when we expect to announce our results for the year to 31 August 2008."
For further information, please contact:
| Fulcrum Pharma plc | |
| Geoffrey Smith, Finance Director | Tel: 0870 710 7152 |
| Seymour Pierce | |
| Jonathan Wright | Tel: 0207 107 8000 |
About Fulcrum Pharma plc
Fulcrum Pharma plc is a drug development and regulatory services business that provides global expertise to achieve drug development and regulatory approval milestones. Fulcrum Pharma offers immediate access to a highly credible, integrated development team that provides strategic and operational leadership required to ensure that new drugs move smoothly from discovery research to product approval.
Fulcrum Pharma is listed on the AIM Market of the London Stock Exchange having successfully floated in March 2000.